October 18-20 | Tucson, AZ

The Research Institution GAP Fund and Accelerator Program Summit

Bayer partners with U Washington gap funded treatment

Get our GAP Insights Newsletter

Join Upcoming Events

October 18-20, 2023 / Tucson, AZ
The annual summit for research institution gap fund and accelerator programs, including proof of concept programs, startup accelerators, and university venture funds

The Story

A new licensing agreement will help farmers and veterinarians fight early-life diarrhea in dairy and beef cattle.

Bayer Animal Health and ParaTheraTech (PTT) have signed a global agreement to advance new Cryptosporidiosis treatment options for these farm animals.

Bayer will develop and commercialize novel compounds based on knowledge and intellectual property licensed by PTT from the University of Washington (UW).

According to the company, Cryptosporidium is a highly infectious diarrhea pathogen and is one of the main causes of death in young calves. The problem can be observed at 30 to 70 percent of the world’s farms.

“Cryptosporidiosis is considered one of the biggest unsolved parasite problems in dairy cattle,” said Douglas Hutchens, DVM, Bayer Animal Health’s chief veterinary officer and head of drug discovery and external innovation.

“The license agreement will enable us to support farmers and veterinarians in tackling this health and well-being concern: early-life diarrhea caused by Cryptosporidium.”

Suggested Veterinary Products

UW assisted PTT with patent filing and strategy, provided an Innovation Gap Fund grant, helped with other funding, and supported the company in licensing exclusive rights to the compound.


Source: Bayer, ParaTheraTech partner to improve treatment of early-life diarrhea in calves – Veterinary Practice News

Get the Report

More GAP News